PhaseV Raises $50M to Revolutionize AI Powered Clinical Trials
AI-driven clinical development platform PhaseV has successfully raised $50 million in a Series A funding round led by Accel and Insight Partners, with participation from Viola Ventures, EXOR, and LionBird.
This latest investment brings PhaseV’s total funding to $65 million, reinforcing confidence in the company’s potential to revolutionize clinical trials through advanced AI solutions.
PhaseV CEO: ‘We’re Transforming Clinical Trials with AI’ Following $50M Funding Round
PhaseV’s platform leverages AI-powered tools to optimize clinical trial processes from planning to execution. The platform’s four core applications include Trial Optimization, Causal Machine Learning, Causal Disease Modeling, and Clinical Operations.
These tools aim to reduce trial costs by up to 50%, shorten participant enrollment timelines by 40%, and increase success rates by nearly a third. “Traditional clinical trial methods are no longer sustainable,” said Raviv Pryluk, CEO and co-founder of PhaseV.
“Our platform leverages cutting-edge AI to streamline trial processes, empowering pharmaceutical companies to accelerate the delivery of life-saving treatments more efficiently.”
Headquartered in Boston and Tel Aviv, PhaseV currently partners with over 30 pharmaceutical and biotech companies, providing AI-driven solutions across more than 20 therapeutic areas, including oncology, neurology, and rare diseases.
The new funding will be used to expand PhaseV’s operations, enhance its product offerings, and scale go-to-market strategies in the U.S. and Europe.
The company also plans to deepen commercial partnerships and further advance its AI capabilities to disrupt the clinical development landscape.
